Compare · Ingredients

Alpha Arbutin vs Cysteamine

Alpha Arbutin: Targets melanin production; clinical data mainly involve combination creams. Cysteamine: Can reduce melasma pigmentation in tested topical formulas.

Research updated 2026-10-25

Four alpha arbutin products lined up on white: three dropper serums and a pink cream tube

Four cysteamine products: a Senté tube, an Omic+ cream and box, a 5% cysteamine serum dropper and a Cyspera bottle

Which one?At a glance What it helps Diagrams Using both Strengths Results Safety How it works Questions

Which one is right for you?

Choose Alpha Arbutin if…

Consider for uneven tone; do not assume it matches prescription pigment treatments.

Mild uneven tone or dark marks
You want a gentler pigment option
You use daily sunscreen

Choose Cysteamine if…

Consider for diagnosed melasma when a suitable topical option is needed.

Diagnosed melasma
Hydroquinone isn’t suitable
You can follow short-contact wash-off

Fine together

Can you use both?

They can share a pigment routine. Use cysteamine as directed (short contact) and arbutin at another time of day.

At a glance

● Alpha Arbutin

● Cysteamine

Type

Pigment-targeting ingredient

Pigment-targeting active

What it does

Targets melanin production; clinical data mainly involve combination creams.

Can reduce melasma pigmentation in tested topical formulas.

Best for

Melasma

Melasma

Studied concentrations

A trial used 5% alpha-arbutin plus 2% kojic acid; this is not a recommended home strength.

5% cream in controlled melasma trials; contact instructions vary by product.

When to use

On the schedule specified for the product or prescribed treatment.

On the schedule specified for the product or prescribed treatment.

Time to results

Usually assessed over 8–16 weeks

Usually assessed over 8–16 weeks

Irritation

May cause irritation or a rash; choose a compliant commercial formula.

Odour, stinging and irritation may limit use; follow wash-off instructions.

Sensitive skin

Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.

Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.

Available

Prescription or cosmetic status depends on the active, formula and country; check the label.

Prescription or cosmetic status depends on the active, formula and country; check the label.

What it helps

Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.

Evidence level

Alpha Arbutin

Cysteamine

Moderate evidenceSome supportive research

—

Flat tan patches with soft irregular edges across the forehead and upper cheek of an adult with light skin, the surface completely smooth.

Melasma

A placebo-controlled trial found reduced pigmentation with 5% cream.

Limited evidenceEarly or small studies

Flat tan patches with soft irregular edges across the forehead and upper cheek of an adult with light skin, the surface completely smooth.

Melasma

A small trial supports a combined alpha-arbutin and kojic acid cream.

—

Insufficient evidence

Flat light-brown residual marks on a fair cheek.

Post-Inflammatory Hyperpigmentation

Independent benefit for post-acne marks is not established by these studies.

AI-generated educational illustration of Sun Spots: 1. Sun Spots Header — Light Skin; Lighter skin. Not a clinical photograph.

Sun Spots

The cited melasma and laboratory studies do not establish sun-spot clearance.

The front of a forearm on fair skin. Two pale patches with sharp edges sit against lightly tanned skin, and the difference between the patch and the skin around it is subtle.

Vitiligo

The reviewed sources do not establish this ingredient as a treatment for this concern.

Inflamed acne on light skin. The spots sit in a patch of pink, and the ring of redness around each one is easy to see. A few have a yellow-white head, and the skin between them is dry and flaking.

Acne

The reviewed sources do not establish this ingredient as a treatment for this concern.

Flat light-brown residual marks on a fair cheek.

Post-Inflammatory Hyperpigmentation

The cited melasma trial does not establish fading of every type of dark mark.

The front of a forearm on fair skin. Two pale patches with sharp edges sit against lightly tanned skin, and the difference between the patch and the skin around it is subtle.

Vitiligo

The reviewed sources do not establish this ingredient as a treatment for this concern.

Sensitive Skin on light skin.

Sensitive Skin

The reviewed sources do not establish this ingredient as a treatment for this concern.

How it works

Alpha Arbutin mechanism diagram. Acts on pigment pathways: Laboratory models show reduced tyrosinase activity. Less melanin is made: Topical results depend on the finished formula. — Open full-size diagram
Diagram explanation and sources
Acts on pigment pathways: Laboratory models show reduced tyrosinase activity. Less melanin is made: Topical results depend on the finished formula.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Source 1 · Source 2

Cysteamine mechanism diagram. Affects melanin formation: Cysteamine acts through several pigment pathways. May help melasma: The formula, contact time and tolerance matter. — Open full-size diagram
Diagram explanation and sources
Affects melanin formation: Cysteamine acts through several pigment pathways. May help melasma: The formula, contact time and tolerance matter.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Source 1

Using both in one routine

Built from where each one usually sits in a routine. Introduce one at a time.

Morning

Step 1

Cleanser

Step 2

Alpha ArbutinMorning or night

Step 3

Moisturizer

Step 4

Sunscreen

Night

Step 1

Cleanser

Step 2

Alpha ArbutinMorning or night

Step 3

CysteamineNight

Step 4

Moisturizer

Strengths and forms

Concentrations

Alpha-arbutin percentages need a regional and product-type context. EU cosmetic limits are 2% in face creams and 0.5% in body lotions; these are safety limits, not proven optimal treatment doses.

0.5%

2%

EU body-lotion ceiling

A maximum for the specified EU product category, not a minimum effective concentration.

EU face-cream ceiling

A maximum for the specified EU product category. It does not establish that 2% will work better than every lower-strength formula.

Choosing a strength: Check that the ingredient is alpha-arbutin. Beta-arbutin has different specifications and should not share the same strength scale.

Higher strengths: A higher concentration in a clinical combination study does not override current cosmetic restrictions or establish safe home use.

Formula matters: The extract or ingredient identity, purity and the finished formula matter. Hydroquinone impurities must be controlled.

5% cysteamine cream is the main concentration studied for melasma. Contact time is product-specific; some studied formulas are short-contact treatments rather than overnight creams.

5%

Studied melasma cream

Controlled trials studied this strength. One short-contact trial used a specific cream; follow the current product’s instructions rather than copying a study schedule.

Choosing a strength: Choose a finished topical product with clear instructions for how long to leave it on and when to rinse.

Higher strengths: There is no established benefit from escalating beyond the studied strength. Burning, redness or a persistent rash are reasons to stop and reassess.

Formula matters: Stabilization, the base cream and exposure time affect tolerability. Different cysteamine formulations need not have identical instructions.

Forms

Serum · Cream

Cream

When you’ll see results

Approximate windows, not promises.

● Alpha Arbutin

● Cysteamine

First few weeks

First few weeksAssess tolerance first; pigment change is usually slower.

First few weeksAssess tolerance first; pigment change is usually slower.

4–8 weeks

4–8 weeksSome studied regimens begin showing pigment improvement.

4–8 weeksSome studied regimens begin showing pigment improvement.

8–12 weeks

8–12 weeksA useful review point for benefit and irritation.

8–12 weeksA useful review point for benefit and irritation.

3–6 months

3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.

3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.

6–12 months

6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.

6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.

Safety and sensitive skin

Common reactions

May cause irritation or a rash; choose a compliant commercial formula.

Odour, stinging and irritation may limit use; follow wash-off instructions.

When to stop

Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.

Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.

Sensitive or inflamed skin

Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.

Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.

Important limits

Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.

Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.

Pregnancy

Because it releases small amounts of hydroquinone, ask rather than assume; pregnancy-specific data are limited. Ask the doctor managing your pregnancy. Azelaic acid and strict sun protection are the usual suggestions meanwhile.

Data in pregnancy are limited; ask the clinician managing your pregnancy before using.

How it works

In the skin

On the skin. The finished product delivers alpha arbutin in a particular vehicle.

Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.

Conversion. No activation step is established as necessary for its intended topical role.

Skin response. Laboratory models show reduced tyrosinase activity and melanin production; clinical delivery and formula matter.

Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.

On the skin. The finished product delivers cysteamine in a particular vehicle.

Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.

Conversion. No activation step is established as necessary for its intended topical role.

Skin response. Acts on pigment-related pathways; the cream, contact time and tolerance influence its practical effect.

Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.

Getting in

Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.

Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.

Molecule size

Alpha Arbutin · 272 Da

Cysteamine · 77 Da

Smaller than 500 Da passes the outer skin more easily. Size isn’t an effectiveness score.

500 Da guideline

Common questions

Alpha Arbutin:What should I choose alpha arbutin for?

Consider for uneven tone; do not assume it matches prescription pigment treatments.

Alpha Arbutin:How strong is the evidence?

A 30-person split-face trial tested alpha-arbutin together with kojic acid. Laboratory results cannot establish clinical efficacy alone, and nonsignificant differences do not prove equivalence.

Cysteamine:What should I choose cysteamine for?

Consider for diagnosed melasma when a suitable topical option is needed.

Cysteamine:How strong is the evidence?

A small placebo-controlled study supports 5% cream over four months. Active-comparator studies are small and do not prove equal efficacy to hydroquinone. The mass shown refers to the free base, not its hydrochloride salt.

Sources

Sources and further reading

Dermapedia on YouTube